We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
DexCom, Inc (DXCM) is a leading diagnostics & research business with stocks listed in the US. It opened the day at US$411.91 after a previous close of US$412.45. During the day the price has varied from a low of USD411.1217 to a high of USD419.19. The latest price was USD418.29 (25 minute delay). DexCom is listed on the NASDAQ. All prices are listed in US Dollars.
How to buy shares in DexCom
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for DexCom. Find the share by name or ticker symbol: DXCM. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until DexCom reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$382.91, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of DexCom, depending on your broker.
- Check in on your investment. Congratulations, you own a part of DexCom. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- DexCom key stats
- Compare share trading platforms
- Is DexCom stock a buy or sell?
- DexCom performance over time
- Can I short DexCom shares?
- Is DexCom suitable for ethical investing?
- Are DexCom shares over-valued?
- DexCom's financials
- How volatile are DexCom shares?
- Does DexCom pay a dividend?
- Other common questions
DexCom share priceUse our graph to track the performance of DXCM stocks over time.
DexCom shares at a glance
|52-week range||US$305.63 - US$456.23|
|50-day moving average||US$368.5189|
|200-day moving average||US$371.4171|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$5.205|
Compare share trading platforms to buy stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy DexCom stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
DexCom price performance over time
|1 month (2021-05-21)||22.27%|
|3 months (2021-03-19)||21.37%|
|6 months (2020-12-18)||16.66%|
|1 year (2020-06-19)||2.18%|
|2 years (2019-06-20)||168.72%|
|3 years (2018-06-20)||315.59%|
|5 years (2016-06-20)||441.55%|
Is DexCom under- or over-valued?
Valuing DexCom stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DexCom's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
DexCom's P/E ratio
DexCom's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 78x. In other words, DexCom shares trade at around 78x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
DexCom's PEG ratio
DexCom's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 11.7433. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DexCom's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
DexCom's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$374.4 million.
The EBITDA is a measure of a DexCom's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||US$2 billion|
|Operating margin TTM||15.39%|
|Gross profit TTM||US$1.3 billion|
|Return on assets TTM||5.7%|
|Return on equity TTM||36.23%|
|Market capitalisation||US$39 billion|
TTM: trailing 12 months
Shorting DexCom shares
There are currently 3.7 million DexCom shares held short by investors – that's known as DexCom's "short interest". This figure is 1.6% down from 3.7 million last month.
There are a few different ways that this level of interest in shorting DexCom shares can be evaluated.
DexCom's "short interest ratio" (SIR)
DexCom's "short interest ratio" (SIR) is the quantity of DexCom shares currently shorted divided by the average quantity of DexCom shares traded daily (recently around 950795.87628866). DexCom's SIR currently stands at 3.88. In other words for every 100,000 DexCom shares traded daily on the market, roughly 3880 shares are currently held short.
However DexCom's short interest can also be evaluated against the total number of DexCom shares, or, against the total number of tradable DexCom shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DexCom's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 DexCom shares in existence, roughly 40 shares are currently held short) or 0.0384% of the tradable shares (for every 100,000 tradable DexCom shares, roughly 38 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against DexCom.
Find out more about how you can short DexCom stock.
DexCom's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like DexCom.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
DexCom's total ESG risk score
Total ESG risk: 29.18
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and DexCom's overall score of 29.18 (as at 12/31/2018) is nothing to write home about – landing it in it in the 50th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like DexCom is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
DexCom's environmental score
Environmental score: 10.43/100
DexCom's environmental score of 10.43 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that DexCom is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
DexCom's social score
Social score: 17.04/100
DexCom's social score of 17.04 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that DexCom is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
DexCom's governance score
Governance score: 13.2/100
DexCom's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that DexCom is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
DexCom's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. DexCom scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that DexCom has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||29.18|
|Total ESG percentile||50.12|
|Environmental score percentile||6|
|Social score percentile||6|
|Governance score percentile||6|
|Level of controversy||2|
DexCom share dividends
We're not expecting DexCom to pay a dividend over the next 12 months.
DexCom share price volatility
Over the last 12 months, DexCom's shares have ranged in value from as little as US$305.63 up to US$456.23. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DexCom's is 0.7511. This would suggest that DexCom's shares are less volatile than average (for this exchange).
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Frequently asked questions
More guides on Finder
THE ICONIC x Finder: Huge 30% off sale + 5 things to shop right now
THE ICONIC's massive sale is exclusive to Finder members and applies to over 40,000 must-have items.
Why the BHP, Rio and FMG share prices are rising
Shares in mining giants BHP, Rio Tinto and Fortescue Metals have climbed between 10%-16% in the last 6 months.
Finder Daily Deals: The 5 best online deals in Australia today
Today's best Finder Daily deals include: $1,000 off Dell gaming laptops, 30% off kids toys, win $10,000 with Optus.
eBay EOFY sales: Best deals from Apple, KitchenAid and more
Score up to 65% off best-selling products with these top end of financial year offers.
Thinking about teeth aligners? Here’s how to make them more affordable
SPONSORED: Perfect teeth could be in closer reach than you think.
Your first look at the Billie Eilish x Air Jordan 1 sneaker collab
Featuring Billie's signature shade, here's what you need to know if you want to cop these kicks.
Amazon Prime Day 2021: Don’t miss these deals on 21 June
Amazon Prime Day is returning to Australia in the first half of 2021. Here are six online deals you need to know about.
How to buy TitanSwap (TITAN) in Australia
This guide will show you step-by-step instructions on how to buy the TitanSwap (TITAN) token as well as a list of exchanges you can trade it on.
Canterbury Bulldogs vs St George Illawarra Dragons NRL: Start time and watch free
The one-win Bulldogs return after a bye, hopefully refreshed and ready to meet the Dragons.
NSW first home owners tax reform offers 25K grants
First home buyers in NSW could be given up to $25,000 towards their first home purchase – find out if you're eligible.
Ask an Expert